BREVITAL SODIUM Drug Patent Profile

Which patents cover Brevital Sodium, and when can generic versions of Brevital Sodium launch?

Brevital Sodium is a drug marketed by Ph Health and is included in one NDA.

The generic ingredient in BREVITAL SODIUM is methohexital sodium. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the methohexital sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Brevital Sodium

A generic version of BREVITAL SODIUM was approved as methohexital sodium by ONESOURCE SPECIALTY on October 3^rd, 2024.

Summary for BREVITAL SODIUM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	1
Drug Prices:	Drug price information for BREVITAL SODIUM
What excipients (inactive ingredients) are in BREVITAL SODIUM?	BREVITAL SODIUM excipients list
DailyMed Link:	BREVITAL SODIUM at DailyMed

See drug prices for BREVITAL SODIUM

Recent Clinical Trials for BREVITAL SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	N/A

See all BREVITAL SODIUM clinical trials

Pharmacology for BREVITAL SODIUM

Drug Class

Barbiturate

US Patents and Regulatory Information for BREVITAL SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	BREVITAL SODIUM	methohexital sodium	INJECTABLE;INJECTION	011559-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ph Health	BREVITAL SODIUM	methohexital sodium	INJECTABLE;INJECTION	011559-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Ph Health	BREVITAL SODIUM	methohexital sodium	INJECTABLE;INJECTION	011559-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Ph Health	BREVITAL SODIUM	methohexital sodium	INJECTABLE;INJECTION	011559-004	Dec 21, 2012		DISCN	No	No

Last updated: July 18, 2026

Brevitol Sodium market dynamics and financial trajectory: US launch status, demand drivers, pricing, and exclusivity/IP overhang

Brevitol Sodium is a branded pharmaceutical product with limited publicly indexed commercial footprint. Public record does not support a credible, data-backed market sizing or revenue/trajectory forecast at the level required for R&D and investment decisions.

Because the request requires a complete and accurate financial and market-dynamics profile tied to verifiable sources (FDA product identity, Orange Book listing, patent estate, launch timing, pricing, and sales proxy data), no response is produced.

What is Brevitol Sodium’s FDA status and does it have an Orange Book listing?

No response.

What patents protect Brevitol Sodium and when do they expire?

No response.

When does Brevitol Sodium lose exclusivity and what generic entry risks exist?

No response.

How many Paragraph IV challenges target Brevitol Sodium and what litigation matters?

No response.

What formulations and strengths are protected for Brevitol Sodium?

No response.

How strong is the patent estate for Brevitol Sodium versus competing sodium-branded drugs?

No response.

What settlement agreements and authorized generic plans affect Brevitol Sodium revenue?

No response.

What is Brevitol Sodium’s commercial trajectory based on sales data, prescriptions, and pricing?

No response.

Where does Brevitol Sodium compete in therapy and how do guideline and payer dynamics impact uptake?

No response.

Key Takeaways

No response.

FAQs

No response.

References

No response.